Free CME from PeerView


Continuing Pharmacy Education (CPE) Activities

Credits: 1.0 CME / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?

Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?

Start

Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?

Media: Enduring Material
Activity Release Date: November 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes

Activity Description

This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care.

Target Audience

This activity has been designed to meet the educational needs of the key care team clinicians in the best position to positively impact safety, survival, and QoL outcomes of patients with advanced PC who require ADT, including urologists, medical oncologists, radiation oncologists, nurse practitioners (NPs), physician assistants (PAs), pharmacists, and other allied healthcare professionals.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes
  • Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors
  • Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Daniel J. George, MD
Professor of Medicine and Surgery
Divisions of Medical Oncology and Urology
Duke University Medical Center
Co-Lead, DCI Center for Prostate and Urologic Cancers
Duke Cancer Institute
Durham, North Carolina

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

Funding for this Independent Medical Education Activity is provided from Pfizer Inc and Myovant Sciences Ltd.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-050-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?

Media: Enduring Material
Activity Release Date: November 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes

Activity Description

This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care.

Target Audience

This activity has been designed to meet the educational needs of the key care team clinicians in the best position to positively impact safety, survival, and QoL outcomes of patients with advanced PC who require ADT, including urologists, medical oncologists, radiation oncologists, nurse practitioners (NPs), physician assistants (PAs), pharmacists, and other allied healthcare professionals.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes
  • Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors
  • Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Daniel J. George, MD
Professor of Medicine and Surgery
Divisions of Medical Oncology and Urology
Duke University Medical Center
Co-Lead, DCI Center for Prostate and Urologic Cancers
Duke Cancer Institute
Durham, North Carolina

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

Funding for this Independent Medical Education Activity is provided from Pfizer Inc and Myovant Sciences Ltd.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-050-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

November 15, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Heart Failure Society of America
Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Start

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Activity Description

How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM
  • Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner
  • Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM
  • Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management

Target Audience

This activity has been designed to meet the educational needs of heart failure specialists, cardiovascular surgeons, general cardiologists, internal medicine physicians, family physicians, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other healthcare professionals involved in the management of HCM.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 21, 2022 - November 20, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

It is the policy of HFSA to ensure balance, independence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).

All individuals who serve as faculty, are on a committee, or are in a position to influence the content of a certified CE activity must disclose any relevant financial relationship that might affect the independent, unbiased development and presentation of the CE content.

Chair & Presenter
Milind Desai, MD, MBA
Haslam Family Endowed Chair in CV Medicine
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director, Clinical Operations
Director, HCM Center
Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland, Ohio

Milind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; and Medtronic.

Presenter
Neal K. Lakdawala, MD
Cardiovascular Genetics, Heart Failure and Cardiac Transplantation
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Neal K. Lakdawala, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; Sarepta Therapeutics, Inc.; and Tenaya Therapeutics.

Presenter
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; and Renovacor, Inc.

Planner
Margery Tamas, MPH
PVI, PeerView Institute for Medical Education

Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.

Accreditation, Credit, and Support


 

JAP In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Learners should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.0 MOC contact hour(s) in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Nurses

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

ACPE The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.0 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-016-H04-P.

Reciprocity

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Off-Label Disclosure

This educational activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this educational activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and The Heart Failure Society of America are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this accredited CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Heart Failure Society of America.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Activity Description

How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM
  • Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner
  • Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM
  • Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management

Target Audience

This activity has been designed to meet the educational needs of heart failure specialists, cardiovascular surgeons, general cardiologists, internal medicine physicians, family physicians, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other healthcare professionals involved in the management of HCM.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 21, 2022 - November 20, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

It is the policy of HFSA to ensure balance, independence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).

All individuals who serve as faculty, are on a committee, or are in a position to influence the content of a certified CE activity must disclose any relevant financial relationship that might affect the independent, unbiased development and presentation of the CE content.

Chair & Presenter
Milind Desai, MD, MBA
Haslam Family Endowed Chair in CV Medicine
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director, Clinical Operations
Director, HCM Center
Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland, Ohio

Milind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; and Medtronic.

Presenter
Neal K. Lakdawala, MD
Cardiovascular Genetics, Heart Failure and Cardiac Transplantation
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Neal K. Lakdawala, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; Sarepta Therapeutics, Inc.; and Tenaya Therapeutics.

Presenter
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; and Renovacor, Inc.

Planner
Margery Tamas, MPH
PVI, PeerView Institute for Medical Education

Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.

Accreditation, Credit, and Support


 

JAP In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Learners should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.0 MOC contact hour(s) in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Nurses

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

ACPE The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.0 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-016-H04-P.

Reciprocity

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Off-Label Disclosure

This educational activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this educational activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and The Heart Failure Society of America are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this accredited CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Heart Failure Society of America.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

October 21, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Start

Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Media: Enduring Material
Activity Release Date: October 7, 2022
Activity Expiration Date: October 6, 2023
Time to Complete Activity: 60 minutes

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP.

In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration.

Target Audience

This activity has been designed to meet the educational needs of physicians, nurses, pharmacists, and other clinicians involved in the care of patients with nasal polyps.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy
  • Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders
  • Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Anju T. Peters, MD, MS
Professor of Medicine,
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Anju T. Peters, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; GlaxoSmithKline; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.

Patient/Planner
Rhonda Nelson

Rhonda Nelson has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-039-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Media: Enduring Material
Activity Release Date: October 7, 2022
Activity Expiration Date: October 6, 2023
Time to Complete Activity: 60 minutes

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP.

In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration.

Target Audience

This activity has been designed to meet the educational needs of physicians, nurses, pharmacists, and other clinicians involved in the care of patients with nasal polyps.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy
  • Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders
  • Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Anju T. Peters, MD, MS
Professor of Medicine,
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Anju T. Peters, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; GlaxoSmithKline; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.

Patient/Planner
Rhonda Nelson

Rhonda Nelson has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-039-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

October 07, 2022
Credits: 1.0 CME / NCPD / CPE
University of Florida College of Medicine
A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

Start

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes


Activity Description and Educational Objectives

Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Traditionally used treatments for gMG are broadly immunosuppressive, do not target pathogenic immunoglobulin G (IgG) autoantibodies, and provide insufficient symptom relief with significant side effects. Fortunately, advances in the understanding of gMG pathogenesis are leading to the development of new treatment options, including neonatal Fc receptor (FcRn) modulators such as the recently approved efgartigimod, and rozanolixizumab, which recently completed phase 3 trials. As with all new and emerging therapeutics, it is important for clinicians to remain abreast of the latest data.

At a recent live event, a multidisciplinary panel of experts compared the safety, efficacy, and tolerability of new treatment options with traditional therapies for gMG. Audience members received expert advice from the perspective of a neurologist, pharmacist, and infusion nurse, with the goal of providing their patients with individualized care through FcRn modulation therapy.

Upon completion of this activity, participants should be better able to:

  • Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG)
  • Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
  • Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing

Target Audience

This activity has been designed to meet the educational needs of neurology specialists (neuromuscular, neuroimmunology, neuro-ophthalmology, and general neurology), nurse practitioners, physician assistants, infusion nurses, pharmacists, and other clinicians involved in the management of gMG.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: October 2, 2022 - November 1, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.

Chair & Presenter
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina
Chapel Hill, North Carolina

James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Toleranzia AB; and UCB Inc.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; argenx; Cartesian Therapeutics, Inc.; Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered Outcomes Research Institute; and UCB Inc.
Other Financial or Material Support in the form of Stock dividends from General Electric Company; GlaxoSmithKline; Johnson & Johnson Services, Inc.; and Pfizer.

Presenter
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Evolve Biologics; Grifols, S.A.; Koru Pharmaceuticals Co., LTD.; Octapharma AG; Pfizer; and Takeda Pharmaceuticals U.S.A., Inc.

Presenter

Stephanie Iyer, PharmD, CPP, BCACP
Clinical Pharmacist Practitioner, UNC Neurology Clinic
UNC Healthcare
Department of Pharmacy
Chapel Hill, North Carolina

Stephanie Iyer, PharmD, CPP, BCACP, has no financial interests/relationships or affiliations in relation to this activity.

Accreditation, Credit, and Support

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an educational grant from argenx US, Inc.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and TBD contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-038-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the University of Florida College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the University of Florida College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes


Activity Description and Educational Objectives

Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Traditionally used treatments for gMG are broadly immunosuppressive, do not target pathogenic immunoglobulin G (IgG) autoantibodies, and provide insufficient symptom relief with significant side effects. Fortunately, advances in the understanding of gMG pathogenesis are leading to the development of new treatment options, including neonatal Fc receptor (FcRn) modulators such as the recently approved efgartigimod, and rozanolixizumab, which recently completed phase 3 trials. As with all new and emerging therapeutics, it is important for clinicians to remain abreast of the latest data.

At a recent live event, a multidisciplinary panel of experts compared the safety, efficacy, and tolerability of new treatment options with traditional therapies for gMG. Audience members received expert advice from the perspective of a neurologist, pharmacist, and infusion nurse, with the goal of providing their patients with individualized care through FcRn modulation therapy.

Upon completion of this activity, participants should be better able to:

  • Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG)
  • Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
  • Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing

Target Audience

This activity has been designed to meet the educational needs of neurology specialists (neuromuscular, neuroimmunology, neuro-ophthalmology, and general neurology), nurse practitioners, physician assistants, infusion nurses, pharmacists, and other clinicians involved in the management of gMG.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: October 2, 2022 - November 1, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.

Chair & Presenter
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina
Chapel Hill, North Carolina

James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Toleranzia AB; and UCB Inc.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; argenx; Cartesian Therapeutics, Inc.; Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered Outcomes Research Institute; and UCB Inc.
Other Financial or Material Support in the form of Stock dividends from General Electric Company; GlaxoSmithKline; Johnson & Johnson Services, Inc.; and Pfizer.

Presenter
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Evolve Biologics; Grifols, S.A.; Koru Pharmaceuticals Co., LTD.; Octapharma AG; Pfizer; and Takeda Pharmaceuticals U.S.A., Inc.

Presenter

Stephanie Iyer, PharmD, CPP, BCACP
Clinical Pharmacist Practitioner, UNC Neurology Clinic
UNC Healthcare
Department of Pharmacy
Chapel Hill, North Carolina

Stephanie Iyer, PharmD, CPP, BCACP, has no financial interests/relationships or affiliations in relation to this activity.

Accreditation, Credit, and Support

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an educational grant from argenx US, Inc.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and TBD contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-038-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the University of Florida College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the University of Florida College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

October 02, 2022
Sagar Lonial, MD, FACP
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Start

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies


Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease
  • Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others
  • Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through independent medical education grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-103-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies


Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease
  • Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others
  • Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through independent medical education grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-103-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 29, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Start

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
  • Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
  • Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.; Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb; EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.; ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics; MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers Squibb.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
  • Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
  • Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.; Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb; EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.; ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics; MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers Squibb.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 29, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Start

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens
  • Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL
  • Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; and Merck & Co., Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-104-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Co-Chair/Planner
Deborah M. Stephens, DO
Associate Professor
Director for Lymphoid Malignancies Program
Division of Hematology and Hematologic Malignancies
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

Deborah M. Stephens, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; CSL Behring; Celgene Corporation; Epizyme, Inc.; Genentech, Inc.; Lilly; and TG Therapeutics, Inc.
Grant/Research Support from Acerta Pharma; Juno Pharmaceuticals; MingSight Pharmaceuticals, Inc.; Newave Pharmaceutical Inc.; and Novartis Pharmaceuticals Corporation.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens
  • Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL
  • Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; and Merck & Co., Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-104-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Co-Chair/Planner
Deborah M. Stephens, DO
Associate Professor
Director for Lymphoid Malignancies Program
Division of Hematology and Hematologic Malignancies
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

Deborah M. Stephens, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; CSL Behring; Celgene Corporation; Epizyme, Inc.; Genentech, Inc.; Lilly; and TG Therapeutics, Inc.
Grant/Research Support from Acerta Pharma; Juno Pharmaceuticals; MingSight Pharmaceuticals, Inc.; Newave Pharmaceutical Inc.; and Novartis Pharmaceuticals Corporation.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 29, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Start

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Media: Enduring Material
Activity Release Date: September 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS
  • Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS
  • Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS
  • Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-100-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Co-Chair/Planner
Guillermo Garcia-Manero, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Other Financial or Material Support as Consultant or Advisory Board or Data and Safety Monitoring Committee for AbbVie; Agios Pharmaceuticals Inc.; Amgen Inc.; AstraZeneca; Astellas Pharma US, Inc.; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb; Catamaran; Celgene Corporation; F. Hoffmann-La Roche AG; GlaxoSmithKline; Helsinn Healthcare; Janssen Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Mesoblast Ltd; Novartis Pharmaceuticals Corporation; Pfizer; Syndax Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited-IRC Chair.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Media: Enduring Material
Activity Release Date: September 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS
  • Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS
  • Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS
  • Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-100-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Co-Chair/Planner
Guillermo Garcia-Manero, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Other Financial or Material Support as Consultant or Advisory Board or Data and Safety Monitoring Committee for AbbVie; Agios Pharmaceuticals Inc.; Amgen Inc.; AstraZeneca; Astellas Pharma US, Inc.; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb; Catamaran; Celgene Corporation; F. Hoffmann-La Roche AG; GlaxoSmithKline; Helsinn Healthcare; Janssen Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Mesoblast Ltd; Novartis Pharmaceuticals Corporation; Pfizer; Syndax Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited-IRC Chair.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 27, 2022
Credits: 1.0 CME / NCPD / CPE
AGA Institute
An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

Start

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

Activity Description and Educational Objectives

In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation.

You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options.

Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction.

Upon completion of this activity, participants should be better able to:

  • Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC
  • Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents
  • Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, obstetricians, gynecologists, nurses, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with irritable bowel syndrome.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: September 12, 2022 - September 11, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The American Gastroenterological Association (AGA) Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.

Chair
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Ardelyx; QOL Medical, LLC; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Salix Pharmaceuticals.

Patient Advocate
Johannah Ruddy, MEd

Johannah Ruddy, MEd, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Mahana Therapeutics, Inc.
Speaker for AbbVie Inc.; Mahana Therapeutics, Inc.; and Salix/Bausch Health Companies Inc.
Other Financial or Material Support as an independent contractor for Salix/Bausch Health Companies Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The AGA Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an independent educational grant from AbbVie and Ironwood Pharmaceuticals.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-032-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the AGA Institute are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the AGA Institute.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

Activity Description and Educational Objectives

In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation.

You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options.

Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction.

Upon completion of this activity, participants should be better able to:

  • Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC
  • Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents
  • Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, obstetricians, gynecologists, nurses, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with irritable bowel syndrome.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: September 12, 2022 - September 11, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The American Gastroenterological Association (AGA) Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.

Chair
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Ardelyx; QOL Medical, LLC; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Salix Pharmaceuticals.

Patient Advocate
Johannah Ruddy, MEd

Johannah Ruddy, MEd, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Mahana Therapeutics, Inc.
Speaker for AbbVie Inc.; Mahana Therapeutics, Inc.; and Salix/Bausch Health Companies Inc.
Other Financial or Material Support as an independent contractor for Salix/Bausch Health Companies Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The AGA Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an independent educational grant from AbbVie and Ironwood Pharmaceuticals.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-032-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the AGA Institute are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the AGA Institute.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 12, 2022
Credits: 1.0 CME / MOC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

Start

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease


Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: October 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, oncology nurses, pharmacists, and other clinicians involved in the management of patients with MCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings
  • Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease
  • Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; Loxo Oncology, Inc.; and Secura Bio.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie Inc.; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; and Loxo Oncology, Inc.

Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Nirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Epizyme, Inc.; Incyte Corporation; Kite; Lilly; Novartis Pharmaceuticals Corporation; Miltenyi Biotec; and TG Therapeutics, Inc.
Grant/Research Support from Miltenyi Biotec.
Speaker for Incyte Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-041-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease


Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: October 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, oncology nurses, pharmacists, and other clinicians involved in the management of patients with MCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings
  • Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease
  • Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; Loxo Oncology, Inc.; and Secura Bio.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie Inc.; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; and Loxo Oncology, Inc.

Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Nirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Epizyme, Inc.; Incyte Corporation; Kite; Lilly; Novartis Pharmaceuticals Corporation; Miltenyi Biotec; and TG Therapeutics, Inc.
Grant/Research Support from Miltenyi Biotec.
Speaker for Incyte Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-041-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 02, 2022
Credits: 0.5 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

Start

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

Media: Enduring Material
Activity Release Date: August 26, 2022
Activity Expiration Date: August 25, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures.

Target Audience

This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease specialists, and other HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19
  • Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures
  • Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Rupa R. Patel, MD, MPH, DTM&H
PrEP Physician and Researcher
Research Associate Professor (Voluntary)
Division of Infectious Diseases
Washington University
St. Louis, Missouri

Rupa R. Patel, MD, MPH, DTM&H, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with ViiV Healthcare.

Patient Advocate/Planner
Faith Mitchell, MPH
HIV Prevention Specialist
CDC Let’s Stop HIV Together
Campaign Ambassador
Adjunct Professor, Health Services
Trinity Washington University
Washington, DC

Faith Mitchell, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


 

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-037-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

Media: Enduring Material
Activity Release Date: August 26, 2022
Activity Expiration Date: August 25, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures.

Target Audience

This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease specialists, and other HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19
  • Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures
  • Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Rupa R. Patel, MD, MPH, DTM&H
PrEP Physician and Researcher
Research Associate Professor (Voluntary)
Division of Infectious Diseases
Washington University
St. Louis, Missouri

Rupa R. Patel, MD, MPH, DTM&H, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with ViiV Healthcare.

Patient Advocate/Planner
Faith Mitchell, MPH
HIV Prevention Specialist
CDC Let’s Stop HIV Together
Campaign Ambassador
Adjunct Professor, Health Services
Trinity Washington University
Washington, DC

Faith Mitchell, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


 

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-037-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 26, 2022
Credits: 1.0 CME / MOC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Start

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?


Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
  • Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
  • Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
  • Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
  • Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABP MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?


Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
  • Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
  • Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
  • Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
  • Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABP MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 18, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Start

Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Media: Enduring Material
Activity Release Date: July 12, 2022
Activity Expiration Date: July 11, 2023
Time to Complete Activity: 60 minutes

Activity Description

The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncology nurses, advanced practice clinicians, pharmacists, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM)
  • Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM
  • Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Sanofi Genzyme.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-054-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Faculty Disclosures

Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm; Novartis Pharmaceuticals Corporation; Takeda Pharmaceutical Company Limited; and TG Therapeutics.
Grant/Research Support from Bristol Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Faculty/Planner
Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Emory University School of Medicine
Adjunct Faculty Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Charise Gleason, MSN, NP-C, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Pfizer.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Media: Enduring Material
Activity Release Date: July 12, 2022
Activity Expiration Date: July 11, 2023
Time to Complete Activity: 60 minutes

Activity Description

The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncology nurses, advanced practice clinicians, pharmacists, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM)
  • Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM
  • Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Sanofi Genzyme.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-054-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Faculty Disclosures

Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm; Novartis Pharmaceuticals Corporation; Takeda Pharmaceutical Company Limited; and TG Therapeutics.
Grant/Research Support from Bristol Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Faculty/Planner
Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Emory University School of Medicine
Adjunct Faculty Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Charise Gleason, MSN, NP-C, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Pfizer.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

July 12, 2022
Credits: 0.5 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

Start

Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women.

Target Audience

This activity has been designed to meet the educational needs of HIV specialty care providers, primary care providers, and general practitioners (MD/DO, NP, PA), as well as other workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), involved in the care of people at risk for being exposed HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women
  • Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women
  • Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina

David Alain Wohl, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Patient/Planner
Benneth Chukwu

Benneth Chukwu has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Taylor Chandler Walker, BC-TCT

Taylor Chandler Walker, BC-TCT, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Omar Martinez, JD, MPH, MS

Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-027-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women.

Target Audience

This activity has been designed to meet the educational needs of HIV specialty care providers, primary care providers, and general practitioners (MD/DO, NP, PA), as well as other workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), involved in the care of people at risk for being exposed HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women
  • Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women
  • Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina

David Alain Wohl, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Patient/Planner
Benneth Chukwu

Benneth Chukwu has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Taylor Chandler Walker, BC-TCT

Taylor Chandler Walker, BC-TCT, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Omar Martinez, JD, MPH, MS

Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-027-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 21, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

Start

The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

Media: Enduring Material
Activity Release Date: June 17, 2022
Activity Expiration Date: June 16, 2023
Time to Complete Activity: 60 minutes

Activity Description

Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA.

The Late Night inExchange format is designed to meet the educational needs of clinicians with practice-relevant education presented in an engaging multi-faculty discussion format that brings knowledge to life. Through this format, learners will be better able to see how conceptual knowledge of AA and AD translates to actual practice.

Target Audience

This activity has been designed to meet the educational needs of nurses, nurse practitioners, physician assistants, and primary care providers involved in the care and treatment of patients with AD and AA.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities.
  • Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets.
  • Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile.
  • Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.

Faculty/Planner
Lawrence Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
Vice Chair, Department of Dermatology
University of California
Rady Children’s Hospital
San Diego, California

Lawrence Eichenfield, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, LLC; Arcutis Biotherapeutics; Arena Pharmaceuticals, Inc.; ASLAN Pharmaceuticals Pte Ltd; Dermata Therapeutics, Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc.; Pfizer; Reistone Biopharma; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics; Dermavant Sciences, Inc.; Ortho Dermatologics; and Pfizer.
Speakers Bureau participant with Almirall, LLC; Pfizer; and Sanofi/Regeneron Pharmaceuticals Inc.
Stock Shareholder in Dermata Therapeutics, Inc.; Forte Biosciences, Inc.; and Verrica Pharmaceuticals.
Other Financial or Material Support as an executive role (Board of Directors) for Forte Biosciences, Inc. and Verrica Pharmaceuticals.

Faculty/Planner
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Director
UC Irvine Program in Medical Education for the Latino Community (PRIME-LC)
Santa Ana, California

Charles Vega, MD, FAAFP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Johnson & Johnson Services, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Pfizer.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-023-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

Media: Enduring Material
Activity Release Date: June 17, 2022
Activity Expiration Date: June 16, 2023
Time to Complete Activity: 60 minutes

Activity Description

Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA.

The Late Night inExchange format is designed to meet the educational needs of clinicians with practice-relevant education presented in an engaging multi-faculty discussion format that brings knowledge to life. Through this format, learners will be better able to see how conceptual knowledge of AA and AD translates to actual practice.

Target Audience

This activity has been designed to meet the educational needs of nurses, nurse practitioners, physician assistants, and primary care providers involved in the care and treatment of patients with AD and AA.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities.
  • Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets.
  • Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile.
  • Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.

Faculty/Planner
Lawrence Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
Vice Chair, Department of Dermatology
University of California
Rady Children’s Hospital
San Diego, California

Lawrence Eichenfield, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, LLC; Arcutis Biotherapeutics; Arena Pharmaceuticals, Inc.; ASLAN Pharmaceuticals Pte Ltd; Dermata Therapeutics, Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc.; Pfizer; Reistone Biopharma; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics; Dermavant Sciences, Inc.; Ortho Dermatologics; and Pfizer.
Speakers Bureau participant with Almirall, LLC; Pfizer; and Sanofi/Regeneron Pharmaceuticals Inc.
Stock Shareholder in Dermata Therapeutics, Inc.; Forte Biosciences, Inc.; and Verrica Pharmaceuticals.
Other Financial or Material Support as an executive role (Board of Directors) for Forte Biosciences, Inc. and Verrica Pharmaceuticals.

Faculty/Planner
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Director
UC Irvine Program in Medical Education for the Latino Community (PRIME-LC)
Santa Ana, California

Charles Vega, MD, FAAFP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Johnson & Johnson Services, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Pfizer.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-023-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 17, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Start

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Media: Enduring Material
Activity Release Date: June 4, 2022
Activity Expiration Date: July 3, 2023
Time to Complete Activity: 60 minutes

Activity Description

Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease.

Target Audience

This activity has been designed to meet the educational needs of oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma
  • Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma
  • Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Hussein A. Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hussein A. Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Eisai, Inc.; EMD Serono; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and RAPT Therapeutics.
Grant/Research Support from Boxer Capital, LLC.; Bristol Myers Squibb; Eisai, Inc.; Genentech, Inc.; Iovance Biotherapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.

Faculty/Planner
Caroline Robert, MD, PhD
Head, Dermatology Unit
Director, Melanoma Research Team at INSERM U981
Gustave Roussy and Paris Saclay University
Villejuif, France

Caroline Robert, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd.; MSD; Novartis Pharmaceuticals Corporation; Pierre Fabre Group; Pfizer; and Sanofi.

Faculty/Planner
Ahmad A. Tarhini, MD, PhD
Senior Member, Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Chair, ORIEN Scientific Committee & ImmunoOncology Research Subcommittee
Tampa, Florida

Ahmad A. Tarhini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioNTech SE; Bristol Myers Squibb; Clinigen Limited; Eisai, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Instil Bio; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Partner Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Acrotech Biopharma; Agenus Inc.; Bristol Myers Squibb; Checkmate Pharmaceuticals; Clinigen Limited; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Nektar Therapeutics; OncoSec Medical Incorporated; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-012-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

ACPE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Media: Enduring Material
Activity Release Date: June 4, 2022
Activity Expiration Date: July 3, 2023
Time to Complete Activity: 60 minutes

Activity Description

Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease.

Target Audience

This activity has been designed to meet the educational needs of oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma
  • Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma
  • Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Hussein A. Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hussein A. Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Eisai, Inc.; EMD Serono; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and RAPT Therapeutics.
Grant/Research Support from Boxer Capital, LLC.; Bristol Myers Squibb; Eisai, Inc.; Genentech, Inc.; Iovance Biotherapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.

Faculty/Planner
Caroline Robert, MD, PhD
Head, Dermatology Unit
Director, Melanoma Research Team at INSERM U981
Gustave Roussy and Paris Saclay University
Villejuif, France

Caroline Robert, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd.; MSD; Novartis Pharmaceuticals Corporation; Pierre Fabre Group; Pfizer; and Sanofi.

Faculty/Planner
Ahmad A. Tarhini, MD, PhD
Senior Member, Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Chair, ORIEN Scientific Committee & ImmunoOncology Research Subcommittee
Tampa, Florida

Ahmad A. Tarhini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioNTech SE; Bristol Myers Squibb; Clinigen Limited; Eisai, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Instil Bio; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Partner Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Acrotech Biopharma; Agenus Inc.; Bristol Myers Squibb; Checkmate Pharmaceuticals; Clinigen Limited; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Nektar Therapeutics; OncoSec Medical Incorporated; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-012-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

ACPE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 04, 2022
Credits: 1.0 CME / NCPD / CPE
PVI, PeerView Institute for Medical Education
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Start

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Media: Enduring Material
Activity Release Date: June 3, 2022
Activity Expiration Date: July 2, 2023
Time to Complete Activity: 60 minutes

Activity Description

For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS.

At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination.

Target Audience

This activity has been designed to meet the educational needs of neurologists, internal and family medicine physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology
  • Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes
  • Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Bruce Cree, MD, PhD, MAS
George A. Zimmermann Endowed Professor in Multiple Sclerosis
Professor of Clinical Neurology
Clinical Research Director
UCSF Weill Institute for Neurosciences
Department of Neurology
University of California San Francisco
San Francisco, California

Bruce Cree, MD, PhD, MAS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Atara Biotherapeutics, Inc.; Autobahn Therapeutics; Avotres, Inc.; Biogen; EMD Serono, Inc.; Horizon Therapeutics plc; Neuron23; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; TG Therapeutics; and Therini Bio, Inc.
Grant/Research Support from Genentech, Inc.

Faculty/Planner
Heidi Crayton, MD
Medical Director
Multiple Sclerosis Center of Greater Washington
Vienna, Virginia

Heidi Crayton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.
Grant/Research Support from Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and sanofi-aventis U.S. LLC.
Speakers Bureau participant with Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-017-L01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Media: Enduring Material
Activity Release Date: June 3, 2022
Activity Expiration Date: July 2, 2023
Time to Complete Activity: 60 minutes

Activity Description

For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS.

At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination.

Target Audience

This activity has been designed to meet the educational needs of neurologists, internal and family medicine physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology
  • Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes
  • Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Bruce Cree, MD, PhD, MAS
George A. Zimmermann Endowed Professor in Multiple Sclerosis
Professor of Clinical Neurology
Clinical Research Director
UCSF Weill Institute for Neurosciences
Department of Neurology
University of California San Francisco
San Francisco, California

Bruce Cree, MD, PhD, MAS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Atara Biotherapeutics, Inc.; Autobahn Therapeutics; Avotres, Inc.; Biogen; EMD Serono, Inc.; Horizon Therapeutics plc; Neuron23; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; TG Therapeutics; and Therini Bio, Inc.
Grant/Research Support from Genentech, Inc.

Faculty/Planner
Heidi Crayton, MD
Medical Director
Multiple Sclerosis Center of Greater Washington
Vienna, Virginia

Heidi Crayton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.
Grant/Research Support from Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and sanofi-aventis U.S. LLC.
Speakers Bureau participant with Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-017-L01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 03, 2022
Credits: 1.0 CME / NCPD / CPE
PVI, PeerView Institute for Medical Education
Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Start

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Media: Enduring Material
Activity Release Date: June 2, 2022
Activity Expiration Date: July 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration.

At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS)
  • Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS
  • Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
  • Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Benjamin M. Greenberg, MD, MHS
Vice Chair of Clinical and Translational Research
Department of Neurology
University of Texas Southwestern Medical Center
Dallas, Texas

Benjamin M. Greenberg, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; EMD Serono, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Genzyme; Horizon Therapeutics plc; Immunovant, Inc.; IQVIA Inc.; Novartis Pharmaceuticals Corporation; Sandoz AG; and Signant Health.
Grant/Research Support from Anokion US Inc.; Clene Inc.; and Regeneron Pharmaceuticals Inc.
Other Financial or Material Support from GenrAB in an executive role/ownership interest.

Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada

Professor Anthony Traboulsee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Novartis AG; and Sanofi Genzyme.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Sanofi Genzyme.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-018-L01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Media: Enduring Material
Activity Release Date: June 2, 2022
Activity Expiration Date: July 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration.

At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS)
  • Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS
  • Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
  • Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Benjamin M. Greenberg, MD, MHS
Vice Chair of Clinical and Translational Research
Department of Neurology
University of Texas Southwestern Medical Center
Dallas, Texas

Benjamin M. Greenberg, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; EMD Serono, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Genzyme; Horizon Therapeutics plc; Immunovant, Inc.; IQVIA Inc.; Novartis Pharmaceuticals Corporation; Sandoz AG; and Signant Health.
Grant/Research Support from Anokion US Inc.; Clene Inc.; and Regeneron Pharmaceuticals Inc.
Other Financial or Material Support from GenrAB in an executive role/ownership interest.

Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada

Professor Anthony Traboulsee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Novartis AG; and Sanofi Genzyme.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Sanofi Genzyme.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-018-L01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 02, 2022
Credits: 0.75 CME / NCPD / CPE
PVI, PeerView Institute for Medical Education
Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity
May 31, 2022
Credits: 0.25 CME / CPE
Medical Learning Institute, Inc.
Making Sense of New Standards for CLL: Pharmacist Insights on Targeted Therapy and the Delivery of Team-Based Care
May 06, 2022

Pages